Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.

ABSTRACT:

Introduction

Geographic access to novel oncology therapies, and the extent to which it may vary by potential sites of care, regions, and population characteristics, is poorly understood. We examined how expanding access to chimeric antigen receptor (CAR) T cell therapy administration sites impacts patient travel distances and time.

Methods

We used geographic information system techniques to calculate shortest travel distance and time between patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) and the nearest CAR T cell therapy administration site in three scenarios: academic hospitals; academic and community multispecialty hospitals; and academic and community multispecialty hospitals plus nonacademic specialty oncology network centers. Main outcome measu

SUBMITTER: Snyder S 

PROVIDER: S-EPMC8408091 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature